Heart Valve Replacement Surgery: Procedure, Recovery, Risks — Cost, Top Hospitals & Success Rates | MyMedicPlus

Heart valve replacement is a cardiac surgical or transcatheter procedure in which a diseased native heart valve — unable to function adequately due to stenosis, regurgitation, or a combination — is replaced with a prosthetic valve to restore normal haemodynamic function. It is the definitive treatment for severe valve disease that has caused or is at risk of causing heart failure, symptoms, or sudden death. The most commonly replaced valves are the aortic valve (the most prevalent valve disease requiring surgery in Western countries) and the mitral valve, though tricuspid and pulmonary valve replacement are performed in specific clinical scenarios.

Surgical heart valve replacement is traditionally performed via median sternotomy with the patient on cardiopulmonary bypass — the heart is stopped, cooled, and the valve excised and replaced with the chosen prosthesis under direct vision. Minimally invasive approaches through smaller upper hemisternotomy or right mini-thoracotomy incisions have been adopted at many specialist valve centres, offering equivalent safety with reduced blood loss, shorter ICU stay, and faster recovery. Transcatheter aortic valve implantation (TAVI) has transformed the management of severe aortic stenosis, delivering a bioprosthetic valve percutaneously via the femoral artery without open heart surgery — now approved for all risk categories from prohibitive to low surgical risk.

The choice between mechanical and biological (bioprosthetic) valve prosthesis is one of the most important decisions in valve surgery. Mechanical valves (St. Jude Medical, On-X, CarboMedics) are extremely durable but require lifelong warfarin anticoagulation with its associated bleeding and monitoring burden. Biological valves (Magna Ease, Intuity, Perimount — surgical; Evolut, SAPIEN — transcatheter) do not require warfarin in most patients but have a shorter lifespan (10–20 years) before structural valve deterioration necessitates re-replacement. Shared decision-making incorporating patient age, lifestyle, comorbidities, and preferences is essential in prosthesis selection.

Aortic valve replacement is the primary treatment for severe aortic stenosis — the most common surgical valve disease in developed countries — affecting approximately 3% of people above age 65 and rising sharply with age. Severe aortic stenosis is defined by aortic valve area below 1 cm² with mean gradient above 40 mmHg or jet velocity above 4 m/s. When symptoms (angina, syncope, heart failure) develop, 2-year survival without intervention falls to 50%; aortic valve replacement restores near-normal survival. Aortic valve replacement is also performed for severe aortic regurgitation causing left ventricular dilatation or dysfunction.

Mitral valve replacement is performed for severe mitral stenosis with unsuitable valve morphology for repair or balloon valvuloplasty (calcified, thickened leaflets, Wilkins score above 8, significant subvalvular disease), and for severe mitral regurgitation when repair is not achievable due to extensive leaflet destruction from rheumatic disease, infective endocarditis, or failed prior repair. Tricuspid valve replacement is occasionally necessary for severe primary tricuspid regurgitation from carcinoid syndrome, endocarditis, or prior tricuspid annuloplasty failure. Pulmonary valve replacement addresses pulmonary regurgitation, most commonly in the long-term follow-up of corrected tetralogy of Fallot, using transcatheter pulmonary valve implantation (Melody, SAPIEN) to avoid repeated open heart surgery.

Surgical aortic valve replacement is indicated for symptomatic severe aortic stenosis (Class I guideline recommendation — highest evidence level), LVEF below 50% in severe aortic stenosis, and very severe disease by echocardiographic criteria or CT calcium scoring in selected asymptomatic patients. TAVI is indicated as an alternative to SAVR when the Heart Team assessment confirms that TAVI is anatomically feasible and provides equivalent or superior outcomes to surgery based on surgical risk, anatomical characteristics, and patient preferences.

Patients unsuitable for surgical valve replacement due to prohibitive surgical risk (STS score above 10%, significant porcelain aorta, prior chest radiation, patient frailty) are candidates for TAVI or transcatheter mitral interventions. Younger patients (below 60 years) may be offered surgical repair before replacement, particularly for the mitral valve, or mechanical valve replacement to avoid future re-operation. Patients with infective endocarditis requiring valve replacement are high-risk surgical cases but require surgery for most indications (uncontrolled infection, large vegetation, systemic embolisation, heart failure from valve destruction); their care must be managed at a specialist Heart Valve Team centre with cardiac surgery capability.

Biological bioprosthetic valves available for surgical implantation include the Carpentier-Edwards Perimount series (bovine pericardium, excellent durability data to 20+ years in older patients), the Edwards Magna Ease (low-profile design, haemodynamically superior), the Medtronic Hancock series, and the rapid-deployment Perceval (self-expanding, no sutures, reducing cross-clamp time). Mechanical valves include the St. Jude Medical (SJM) Regent (bileaflet tilting disc, the most widely implanted mechanical valve globally), On-X valve (requiring less anticoagulation — PROACT Xa trial), and Carbomedics. Stentless biological valves (Toronto SPV, Freedom Solo, Freestyle) are used in selected centres for their superior haemodynamics, particularly in patients with small aortic annuli.

Transcatheter aortic valve options include the balloon-expandable Edwards SAPIEN 3 Ultra (excellent haemodynamics, minimal paravalvular leak with outer skirt, operator-independent sizing) and the self-expanding Medtronic Evolut PRO+/FX (superior early haemodynamics, low pacemaker rates with commissural alignment). For transcatheter mitral valve replacement (TMVR), Tendyne, Intrepid, and Tendyne devices are in advanced clinical trials; transcatheter tricuspid valve replacement devices (TRISCEND, GATE) are in early trials. Valve-in-valve TAVI, where a new TAVI prosthesis is deployed within a failing surgical bioprosthesis, has become an established technique avoiding re-operation in high-risk patients. Transcatheter edge-to-edge repair (TEER) for mitral regurgitation using the MitraClip or PASCAL device offers an alternative to open repair in high-risk patients. Valve-in-valve TAVI — deploying a new transcatheter valve within a failing surgical bioprosthesis — has become an established technique avoiding re-operation in high-risk patients.

Successful aortic valve replacement restores near-normal life expectancy in patients with severe aortic stenosis, particularly those under 75 years. In elderly patients (above 80), AVR doubles 5-year survival compared to conservative management and dramatically improves quality of life — symptomatic improvement occurs within weeks in over 90% of patients. Surgical aortic valve replacement using modern bioprostheses achieves 10-year survival of 55–70% in octogenarians (accounting for competing non-cardiac mortality), with valve-related mortality well below 1% per year. TAVI achieves equivalent outcomes to SAVR in intermediate and high-risk patients and non-inferior or superior outcomes in low-risk patients across multiple trials (PARTNER 3, SURTAVI, CHOICE).

Mitral valve replacement for mitral stenosis achieves immediate haemodynamic normalisation with relief of pulmonary hypertension and improvement in NYHA class in over 90% of patients. Long-term survival following mitral valve replacement is strongly influenced by pre-operative right ventricular function, pulmonary hypertension severity, and AF — patients with preserved RV function and no AF have near-normal long-term survival. Valve-in-valve TAVI for degenerated surgical bioprostheses achieves 1-year mortality of 5–12% depending on patient risk, avoiding the significantly higher mortality (15–25%) of redo open-heart surgery in this elderly high-risk population.

Surgical aortic valve replacement carries 30-day mortality of 1–3% for isolated procedures in low-risk patients at experienced centres, rising to 5–8% in patients above 80 years, those undergoing combined procedures (AVR plus CABG), and redo operations. Stroke risk is 1–3%, acute kidney injury requiring dialysis 1–3%, and new pacemaker requirement 3–5% for SAVR. TAVI-specific complications include stroke (2–4% — slightly higher than SAVR at 30 days in most trials), new permanent pacemaker implantation (3–12% depending on device and anatomy), significant paravalvular leak (below 2% with modern devices), vascular access complications (1–3%), and leaflet thrombosis (detected on CT in 10–15% of TAVI prostheses, though clinical consequences are uncertain).

Long-term complications of valve prostheses include structural valve deterioration (bioprosthetic valves — 30% freedom from reoperation at 20 years in patients below 65), valve thrombosis (mechanical valves — 0.5–1% per year despite anticoagulation), prosthetic valve endocarditis (0.3–0.5% per year — requiring aggressive antibiotic therapy and usually surgical re-replacement), thromboembolism (mechanical valves 0.5–1% per year on adequate anticoagulation), and bleeding from anticoagulation (mechanical valves 1–2% major bleeding per year). Patient-prosthesis mismatch — inadequate prosthetic valve area for the patient's cardiac output demands — may limit haemodynamic benefit and is avoided by careful pre-operative annulus sizing and prosthesis selection.

Postoperative recovery after surgical valve replacement parallels CABG: 24–48 hours in the ICU, 5–7 days total hospitalisation, 6–8 weeks sternal precautions, and 2–3 months to full activity. Anticoagulation management requires close attention: mechanical valve recipients are bridged with heparin until warfarin achieves therapeutic INR (2.0–3.0 for aortic position, 2.5–3.5 for mitral position), with lifelong monthly INR monitoring. Bioprosthetic valve recipients take aspirin and (in some centres) warfarin for 3 months post-implant to cover the endothelialisation period, then aspirin alone.

Echocardiography at 30 days, 12 months, and annually assesses prosthetic valve haemodynamics (gradients, valve area), perivalvular regurgitation, ventricular function, and structural integrity. Cardiac rehabilitation commences 4–6 weeks post-surgery. After TAVI, follow-up echocardiography is typically performed at 30 days and 12 months; antiplatelet therapy (DAPT for 3 months, then aspirin alone) is the standard post-TAVI antithrombotic regimen in the absence of another anticoagulation indication. Endocarditis prophylaxis before dental and surgical procedures is mandatory lifelong for all prosthetic valve recipients.

Isolated aortic valve replacement surgery in the United States costs $80,000–$150,000; TAVI $60,000–$120,000 (prosthetic valve alone costs $32,000–$45,000); mitral valve replacement $90,000–$160,000; and combined CABG plus AVR $120,000–$200,000. These costs create enormous financial burden for uninsured or underinsured patients.

India is the premier destination for medical tourism in heart valve surgery, offering isolated surgical aortic valve replacement (including prosthetic valve, procedure, anaesthesia, and hospitalisation) for $8,000–$15,000 — saving 85–90% versus US costs. TAVI is performed at major Indian cardiac centres (Apollo, Fortis, Medanta) for $20,000–$35,000 using international-brand prostheses, compared to $60,000–$120,000 in the US. Mitral valve surgery costs $10,000–$18,000 in India. Thailand (Bumrungrad) costs $20,000–$40,000 for valve surgery; Turkey (Acibadem) $15,000–$30,000; Germany $40,000–$70,000. All these centres use internationally approved prostheses and have cardiac surgery outcomes data comparable to leading Western centres.

For aortic stenosis, the only effective alternative to valve replacement is transcatheter balloon aortic valvuloplasty (BAV) — a non-surgical procedure that temporarily improves the aortic valve gradient by fracturing calcium deposits with a balloon, without replacing the valve. BAV provides short-term haemodynamic improvement but restenosis typically recurs within 6–12 months; it is used as a bridge to definitive TAVI or surgery in haemodynamically unstable patients, or as palliation in patients unsuitable for any definitive intervention.

For mitral stenosis with suitable valve morphology (Wilkins score below 8, no significant MR, no left atrial thrombus), percutaneous balloon mitral valvuloplasty (PBMV) achieves haemodynamic results equivalent to surgical commissurotomy, avoiding open heart surgery, and is the preferred intervention for these patients in high-volume centres with PBMV expertise. For severe secondary mitral regurgitation in heart failure, optimised GDMT (sacubitril-valsartan, CRT) may reduce MR severity through reverse remodelling, deferring or potentially avoiding mitral intervention. Transcatheter mitral valve repair (MitraClip) is an alternative to replacement for both primary and secondary MR in patients with high surgical risk and anatomically suitable valves.